Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a two-pronged approach to neurological health, focusing on both a potential multiple sclerosis treatment and a dietary supplement aimed at mitigating alcohol's effects. The biopharmaceutical company is developing Lucid-MS, an investigational therapy designed to target PAD2, an enzyme implicated in myelin degradation. Unlike traditional MS treatments that primarily modulate the immune system, Lucid-MS aims to protect and potentially restore the myelin sheath, the protective coating around nerve fibers that is damaged in MS.
The company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 trial of Lucid-MS. To support this development, Quantum BioPharma is collaborating with Massachusetts General Hospital on imaging techniques to better assess the therapy's effects. This partnership is expected to enhance the evaluation of myelin repair in clinical trials, a critical aspect of demonstrating the drug's potential.
In a separate but complementary initiative, Quantum BioPharma has developed unbuzzd, a proprietary dietary supplement designed to support alcohol metabolism and reduce acute intoxication and hangover symptoms. The company cites results from a randomized, placebo-controlled clinical trial that showed promising outcomes. Quantum BioPharma has spun out the over-the-counter version of unbuzzd to Unbuzzd Wellness Inc. (UWI), a company led by industry veterans. Quantum BioPharma retains a 19.84% ownership stake in UWI as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Importantly, Quantum BioPharma retains full rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The dual strategy positions Quantum BioPharma to address neurological health from two angles: a potential disease-modifying therapy for MS and a consumer-focused product for alcohol-related issues. The advancement of Lucid-MS into Phase 2 trials marks a significant step toward a novel treatment that could offer an alternative to current immunomodulatory therapies. The collaboration with Massachusetts General Hospital is particularly noteworthy, as it may provide robust imaging biomarkers to track remyelination, a key goal in MS research.
Meanwhile, unbuzzd addresses a widespread public health concern, with the global market for hangover remedies and alcohol support products growing. By spinning out the OTC version while retaining pharmaceutical rights, Quantum BioPharma can potentially benefit from both consumer sales and future pharmaceutical developments. The royalty structure provides a steady revenue stream that could fund further research.
These developments underscore Quantum BioPharma's commitment to innovation in neurology. As the company progresses with its IND submission and continues to support unbuzzd's market presence, it is positioning itself as a versatile player in the biopharmaceutical landscape. Investors and stakeholders will be watching closely for updates on the Phase 2 trial and the commercial performance of unbuzzd.
